Share Name Share Symbol Market Type Share ISIN Share Description
AstraZeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +29.00p +0.57% 5,152.00p 5,154.00p 5,156.00p 5,172.00p 5,120.00p 5,135.00p 1,932,147 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,627.4 2,876.5 224.3 24.1 65,205.81

AstraZeneca Share Discussion Threads

Showing 10351 to 10373 of 10375 messages
Chat Pages: 415  414  413  412  411  410  409  408  407  406  405  404  Older
DateSubjectAuthorDiscuss
21/7/2017
09:57
Sold half.
philanderer
16/7/2017
10:04
Closed around £51-70 equivalent at current xrates in New York.
steeplejack
14/7/2017
23:00
Should bounce on Monday, especially as RSI was heading to oversold.
bluemango
14/7/2017
22:58
14 JULY 2017 • 9:10PM Pascal Soriot will remain at FTSE 100 pharmaceuticals firm AstraZeneca, sources said on Friday, rebuffing rumours that he was planning a move to rival Israeli drugs giant Teva Pharmaceuticals. Mr Soriot will host a call with analysts on AstraZeneca's second-quarter earnings at the end of the month as planned, AstraZeneca said. A spokesman for AstraZeneca said the company never commented on speculation and did not respond to rumours. AstraZeneca's US-listed shares lifted 4pc on the news, which was first reported by Bloomberg. hTTp://www.telegraph.co.uk/business/2017/07/14/pascal-soriot-looks-set-stay-astrazeneca-chief/
bluemango
14/7/2017
22:06
According to Bloomberg Pascal's staying...... AZN in the USA. +4%
philanderer
14/7/2017
10:14
Markets no something
stevenrevell
14/7/2017
10:05
Aren't the Int results out soon? I know the reasons for the CEO rumoured to leave but shares normally rise into results, is there something that we don't know??
utyinv
13/7/2017
12:34
Citi comment: In the event the CEO's departure is confirmed. Mene Pangalos, current head of AZN research and early development is the highest probability internal candidate, as well as Sean Bohen (CMO), in our view. We also suspect AZN's board has identified additional external candidates as part of the succession planning process. HTTPS://ftalphaville.ft.com/marketslive/2017-07-13/
philanderer
13/7/2017
09:42
If Company was aware of share price sensitive news listing regulations would require them to update Market immediately. Concern is delay in responding to Soriot news and share price movement which suggests an internal battle to persuade Soriot to stay. However, regulations will come into play and force a clarification. Either he stays or AZN rudderless while industry deckchairs realigned - perfect window for opportunist offer!
scallywagkid
13/7/2017
09:15
Agree with Phil - thought his leaving would be a plus not a disaster. Unless he is leaving a few skeletons in the cupboard? Not a golden reign
ganthorpe
13/7/2017
09:14
I think we may get another drop soon and hopefully a bargain
stevenrevell
13/7/2017
08:58
I think the market is making a link between him leaving and the imminent massive news on the lung cancer drug.
billytkid2
13/7/2017
08:42
Cavalry to the rescue ;-) 13th july Citigroup buy tp 6000p 13th july Liberum buy tp 5500p reiterations.
philanderer
13/7/2017
08:40
Is this fella really worth 4% of the market cap !!
philanderer
13/7/2017
00:52
explains the late 3% drop in the States, thanks for the info.
drectly
13/7/2017
00:32
So back under 5000p in the morning then ?
philanderer
12/7/2017
09:05
12th july Jefferies hold tp 5300p cut from 5500p
philanderer
06/7/2017
21:19
AstraZeneca sells off Fairfax campus for $50M HTTP://www.delawareonline.com/story/money/real-estate/2017/07/06/astrazeneca-sells-off-fairfax-campus-55-m/454706001/
philanderer
03/7/2017
13:21
AstraZeneca to rake in more than £450m on two drug sales HTTP://www.telegraph.co.uk/business/2017/07/03/astrazeneca-rake-450m-two-drug-sales/?utm_source=dlvr.it&utm_medium=twitter
philanderer
03/7/2017
10:13
3rd july Barclays 'overweight' tp 6300p up from 6000p
philanderer
30/6/2017
15:21
Drugmakers’ Payments to U.K. Health Groups and Doctors Climb 25% HTTPS://www.bloomberg.com/news/articles/2017-06-30/drugmakers-payments-to-u-k-health-groups-doctors-climb-25?cmpid=socialflow-twitter-business&utm_content=business&utm_campaign=socialflow-organic&utm_source=twitter&utm_medium=social
philanderer
30/6/2017
14:39
30th june Deutsche buy tp 5700p reiterates
philanderer
26/6/2017
17:12
'Pioneering British firm wins patent for 'cancer vaccines' technology' A pioneering British pharmaceutical company has won a European patent for its ‘cancer vaccines’ technology, which if successful could revolutionise treatment of the disease. Scancell, which is listed on London’s AIM market, has been awarded the patent for its DNA ImmunoBody scientific platform, which underpins its pipeline of potential cancer vaccines. .........Much larger FTSE 100 rival AstraZeneca is due to publish eagerly-awaited phase three clinical data this summer from a trial called Mystic, testing one of its own promising IO ‘checkpoint’ therapies in lung cancer patients. HTTP://www.telegraph.co.uk/business/2017/06/26/pioneering-british-firm-wins-patent-cancer-vaccines-technology/
philanderer
Chat Pages: 415  414  413  412  411  410  409  408  407  406  405  404  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170723 04:36:48